Epic Sciences' circulating tumor cell (CTC) no cell left behind™ technology was featured in Cancer Discovery's May 2014 issue. The article discusses how quantifying and characterizing circulating tumor cells (CTC), as a liquid biopsy, is helping doctors to determine the course of therapy and to watch how a patient’s cancer evolves—all with a blood draw.
Mentioned in the article is research that showed CTCs from prostate cancer patients could be used to determine PTEN status using fluorescence in situ hybridization (FISH) to look for the gene in cells captured by the Epic technology. Patients whose tumors have lost PTEN might do better on a therapy that targets the PI3K/AKT pathway.
If you or your organization has a subscription to Cancer Discovery, the full article can be read here.